Letermovir Prophylaxis for CMV DNAemia/Disease after HLA-Mismatched HSCT: A Retrospective Real-World Analysis with Overlap Propensity Score Weighting. (PubMed, Clin Pharmacol Ther) - Dec 5, 2025 - "Overall survival and non-relapse mortality (NRM) were unaffected by letermovir, probably reflecting effective preemptive management and the study's overlap-weighted design. Based on our results, letermovir prophylaxis can effectively reduce CMV DNAemia/disease in HLA-mismatched and mGIAC haplo-HSCT, and may serve as a standard of care for these high-risk patients."
Journal • Real-world evidence • Retrospective data • Bone Marrow Transplantation • Transplantation
|
|
Bor-Sheng Ko; Fei-Yuan Hsiao; Jia-Hau Liu; Ming Yao; Shu-Wen Lin; Xavier Cheng-Hong Tsai; Yee-Chun Chen; Yi-Che Huang
|